Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2bFebruary 10, 2021PsoriasisPsoriatic Arthritis
In head-to-head trial, two biologics differ markedly for control of psoriasisFebruary 4, 2021PsoriasisPsoriatic Arthritis
Guselkumab maintains psoriasis efficacy long after discontinuationJanuary 26, 2021PsoriasisPsoriatic Arthritis
Dermatologist survey spotlights psoriasis care deficiencies in reproductive-age womenJanuary 22, 2021PsoriasisMixed Topics
Deucravacitinib offers biologic-like psoriasis efficacy in oral formJanuary 8, 2021PsoriasisPsoriatic Arthritis
COVID-19 vaccines: Safe for immunocompromised patients?December 17, 2020COVID-19 UpdatesInfectious DiseasesPsoriasisPsoriatic Arthritis
Synovial, skin gene expression differences may explain PsA treatment responsesDecember 11, 2020Psoriatic ArthritisPsoriasis
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritisNovember 30, 2020Psoriatic ArthritisPsoriasis
TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possibleNovember 25, 2020PsoriasisPsoriatic Arthritis
Tildrakizumab for psoriasis shows durable efficacy over 5 yearsNovember 19, 2020PsoriasisPsoriatic Arthritis
Methotrexate users need tuberculosis tests in high-TB areasNovember 8, 2020Psoriatic ArthritisPediatricsAutoimmune DiseasesPsoriasisInfectious Diseases
